Filing Flows › Jaguar Health (JAGX) › Q2 2025
Jaguar Health (JAGX) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 14, 2025
Jaguar Health (JAGX) reported revenue of $3.0M for the second quarter 2025 (Q2 2025), +9% from a year earlier and +35% from the quarter before. Operating margin was -268.8%, net loss $10.6M (354.5% of revenue).
Jaguar Health, Q2 2025: revenue $3.0M (+10% year over year), operating margin -268.8%, net loss $10.6M, operating cash flow −$6.2M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $3.0M | +35% | +9% |
| Operating profit | −$8.0M | — | — |
| Net earnings | −$10.6M | — | — |
| Operating cash flow | −$6.2M | — | — |
What changed
Revenue was $3.0M in Q2 2025, up 9% year over year and up 35% from the previous quarter. Product was the largest line at 99% of revenue. Product added $258K year over year (up 10%), 100% of the total change.
Operating costs exceeded revenue by $8.0M, an operating margin of -268.8%. Total costs grew 11% against revenue growth of 9%. The fastest-growing cost line was Sales & marketing (+62%). The quarter ended with a net loss of $10.6M, narrower than the previous quarter's $10.6M loss. Minority interests bore $153K of it: to shareholders the quarter was a loss of $10.4M.
Operating cash flow was −$6.2M. Non-cash charges added back $478K of depreciation and amortization and $279K of share-based compensation. Working capital and other items added $3.6M.
Questions
What was Jaguar Health's revenue in the second quarter 2025?
Jaguar Health (JAGX) reported revenue of $3.0M for the second quarter 2025 (Q2 2025), +9% from a year earlier and +35% from the quarter before.
Was Jaguar Health profitable in the second quarter 2025?
Operating loss was $8.0M (-268.8% of revenue) and net loss $10.6M.
Source: Jaguar Health 10-Q on SEC EDGAR.